GLP-1 agonists have become useful in many clinical conditions besides T2DM for which it was initially approved, including in patients with obesity (body mass index (BMI) of 30 and above) and patients with BMI of 27 and above with at least one weight-related complication [6]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.